The observational study to investigate serum carnitine level for patients who will receive HCC treatments and liver transplantation

The observational study to investigate serum carnitine level for patients who will receive HCC treatments and liver transplantation - The observational study to investigate serum carnitine level for patients who will receive HCC treatments and liver transplantation

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000039425

Enrollment

200

Registered

2020-02-07

Start date

2020-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma Liver transplantation

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients who will receive HCC treatments or liver transplantation, and older than 20 years 2)Patients who can investigate serum blood tests before and after the treatments 3)Patients who can obtain informed consent

Exclusion criteria

Exclusion criteria: Patients whom the principal investigator judged as inappropriate for the participation of the study

Design outcomes

Primary

Measure	Time frame
To investigate serum carnitine level for patients who will receive HCC treatments and liver transplantation	—

Secondary

Measure	Time frame
1) To investigate the factors which correlate with the transition of serum carnitine level. 2) To investigate the factors affecting the transition of serum carnitine level. 3) To investigate the usefulness of serum carnitine as the tumor marker for HCC 4) To investigate the relation with the serum carnitine level and the prognosis.	—

Countries

Japan

Contacts

Public ContactKomatsu Shohei

Kobe University Graduate School of Medicine Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery

komasho8@med.kobe-u.ac.jp078-382-6302

Outcome results